Related Experiment Video
Updated: Jun 5, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
[Meta-analysis on interleukin-4 receptor α chain Q576R gene polymorphisms and bronchial asthma susceptibility]
Hong Xue1, Kai Sun, Wei-Ping Xie
1Department of Respiratory Medicine, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.
Objective:
to study the association between interleukin-4 receptor α chain (IL-4RA) Q576R polymorphisms and bronchial asthma susceptibility by Meta-analysis.
Methods:
four medical databases, including Pubmed, Embase, CNKI and Wanfang, were searched for the case-control studies about the IL-4RA polymorphisms and bronchial asthma susceptibility. Odds ratios (OR) of IL-4RA Q576R genotype distributions in asthma patients against healthy controls were analyzed in both RR vs QR + QQ model and QR + RR vs QQ model. Analyses were performed for asthma in general and for subgroups based on the atopy status of the asthma population. The sensitivity analysis and the publication bias tests were conducted.
Results:
fifteen case-control studies, with 2675 asthma cases, 1202 atopic asthma cases and 331 nonatopic asthma cases respectively, were identified and all control group genotype frequencies were consistent with Hardy-Weinberg equilibrium. In genotype RR vs QR + QQ model no heterogeneity among the studies was found, while in genotype QR + RR vs QQ model, heterogeneity among these studies was found. These studies were analyzed by fixed-effect model (RR vs QR + QQ model) or random-effect model (QR + RR vs QQ model). The pooled odds ratio of IL-RA Q576R genotype RR vs QR + QQ was 2.02 (95%CI: 1.53 - 2.66), and the pooled odds ratio in this model in the atopic asthma subgroup was 2.26 (95%CI: 1.47 - 3.49), while the pooled odds ratio (QR + RR vs QQ model) was 1.02 (95%CI: 1.06 - 1.53).
Conclusion:
a meta-analysis of results from case-control studies strongly supports the conclusion that IL-4RA Q576R polymorphisms impart a modest yet significant risk for asthma.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Asthma I: Introduction
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations
